Skip to main content
. 2019 May 15;39(5):BSR20190379. doi: 10.1042/BSR20190379

Figure 10. Histopathological examinations of the expression and specific tissue distribution of TGF-β and NF-κB.

Figure 10

(A) Liver sections from the control group with low TGF-β and NF-κB immune positive reaction in the hepatic cells, ×400. (B) Positive control section with moderate staining of TGF-β and NF-κB-positive hepatocytes around the central veins, ×400. (C) Sulfadiazine pretreated section with low staining of TGF-β and NF-κB-positive hepatocytes, ×400. (D) Sulfadiazine post-treated section similar to the pre-treated section with low staining of TGF-β and NF-κB-positive hepatocytes around the central veins, ×400. (E) Nanoparticle pretreated section with no staining of TGF-β and NF-κB-positive hepatocytes, 400×. (F) Nanoparticles post-treated section with low staining of TGF-β and NF-κB-positive hepatocytes, ×400.